XNASICU
Market cap9mUSD
Dec 24, Last price
2.05USD
1D
2.96%
1Q
-54.37%
IPO
-99.25%
Name
SeaStar Medical Holding Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-26m
L+13.99%
CFO
-10m
L+31.96%
Earnings
Apr 14, 2025
Profile
SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||
Revenues | ||||
Cost of revenue | 14,010 | 9,419 | 4,449 | |
Unusual Expense (Income) | ||||
NOPBT | (14,010) | (9,419) | (4,449) | |
NOPBT Margin | ||||
Operating Taxes | 1,000 | (1,000) | ||
Tax Rate | ||||
NOPAT | (14,010) | (9,420) | (4,448) | |
Net income | (26,232) 13.99% | (23,013) 400.72% | (4,596) 40.29% | |
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 6,612 | 10,001 | ||
BB yield | -68.92% | -29.71% | ||
| Debt | ||||
Debt current | 4,744 | 1,178 | 2,378 | |
Long-term debt | 4,337 | 7,652 | 244 | |
Deferred revenue | ||||
Other long-term liabilities | 73,404 | |||
Net debt | 8,905 | 7,054 | 2,112 | |
| Cash flow | ||||
Cash from operating activities | (10,285) | (7,794) | (5,114) | |
CAPEX | ||||
Cash from investing activities | (105,570) | |||
Cash from financing activities | 10,414 | 7,331 | 2,817 | |
FCF | (9,152) | (8,425) | (4,307) | |
| Balance | ||||
Cash | 176 | 47 | 510 | |
Long term investments | 1,729 | |||
Excess cash | 176 | 1,776 | 510 | |
Stockholders' equity | (114,729) | (99,324) | (76,311) | |
Invested Capital | 109,940 | 99,919 | 76,172 | |
ROIC | ||||
ROCE | 292.55% | 3,200.72% | ||
| EV | ||||
Common stock shares outstanding | 867 | 328 | 290 | |
Price | 11.07 -89.20% | 102.50 | ||
Market cap | 9,593 -71.50% | 33,666 | ||
EV | 18,498 | 40,720 | ||
EBITDA | (14,010) | (9,419) | (4,449) | |
EV/EBITDA | ||||
Interest | 1,081 | 630 | 212 | |
Interest/NOPBT | ||||